What Is Recent in Pancreatic Cancer Immunotherapy?

被引：20

作者：

Niccolai, Elena ^{[1
,2
]}

Prisco, Domenico ^{[2
,3
]}

D'Elios, Mario Milco ^{[1
,2
,4
]}

Amedei, Amedeo ^{[1
,2
,4
,5
]}

机构：

[1] Univ Florence, Dept Internal Med, I-50134 Florence, Italy

[2] Azienda Osped Univ Careggi, Dept Biomed, Patol Med Unit, I-50134 Florence, Italy

[3] Univ Florence, Dept Med & Surg Crit Care, I-50134 Florence, Italy

[4] Univ Florence, Ctr Oncol Minimally Invas Surg, I-50134 Florence, Italy

[5] Univ Florence, Dept Internal Med, Div Immunol, I-50134 Florence, Italy

来源：

BIOMED RESEARCH INTERNATIONAL | 2013年 / 2013卷

关键词：

GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; PULSED DENDRITIC CELLS; PERSONALIZED PEPTIDE VACCINATION; HUMAN MONOCLONAL-ANTIBODY; TUMOR-ASSOCIATED ANTIGEN; PHASE-III TRIAL; GM-CSF GENE; TELOMERASE ACTIVITY; IN-VITRO;

D O I：

10.1155/2013/492372

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Pancreatic cancer (PC) represents an unresolved therapeutic challenge, due to the poor prognosis and the reduced response to currently available treatments. Pancreatic cancer is the most lethal type of digestive cancers, with a median survival of 4-6 months. Only a small proportion of PC patients is curative by surgical resection, whilst standard chemotherapy for patients in advanced disease generates only modest effects with considerable toxic damages. Thus, new therapeutic approaches, specially specific treatments such as immunotherapy, are needed. In this paper we analyze recent preclinical and clinical efforts towards immunotherapy of pancreatic cancer, including passive and active immunotherapy approaches, designed to target pancreatic-cancer-associated antigens and to elicit an antitumor response in vivo.

引用

页数：14

共 154 条

[1] Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine [J].

Abou-Alfa, Ghassan K. ;

Chapman, Paul B. ;

Feilchenfeldt, Jonas ;

Brennan, Murray F. ;

Capanu, Marinela ;

Gansukh, Bolorsukh ;

Jacobs, Gria ;

Levin, Adrah ;

Neville, Deirdre ;

Kelsen, David P. ;

O'Reilly, Eileen M. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03) :321-325

[2] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].

ALMOGUERA, C ;

SHIBATA, D ;

FORRESTER, K ;

MARTIN, J ;

ARNHEIM, N ;

PERUCHO, M .

CELL, 1988, 53 (04) :549-554

[3]

Andersen MH, 2001, CANCER RES, V61, P869

[4]

[Anonymous], US CANC STAT 1999 20

[5]

Argani P, 2001, CLIN CANCER RES, V7, P3862

[6]

Armstrong DK, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.07.3494

[7] Dendritic cells as therapeutic vaccines against cancer [J].

Banchereau, J ;

Palucka, AK .

NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :296-306

[8] Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth [J].

Bangard, C ;

Gossmann, A ;

Papyan, A ;

Tawadros, S ;

Hellmich, N ;

Bruns, CJ .

INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (01) :131-138

[9] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[10] MUC1 immunotherapy [J].

Beatson, Richard E. ;

Taylor-Papadimitriou, Joyce ;

Burchell, Joy M. .

IMMUNOTHERAPY, 2010, 2 (03) :305-327

← 1 2 3 4 5 6 7 8 9 10 →